Skip to Main Content

As the Trump administration settled in last year, the White House insisted on fewer regulations — and the Food and Drug Administration delivered, according to a new analysis.

Last year, regulatory actions taken by the agency were only a fraction of the number of actions taken during the Obama administration and in fact dropped to the lowest level of any time in the past 20 years, according to the Health Research Institute at PricewaterhouseCoopers, the consulting firm.


In all, the FDA issued just six new significant regulatory actions in 2017, compared with 30 during the previous year. Moreover, none of those half-dozen actions involved biopharma regulation, but there were 11 actions applicable to life sciences in 2016 and 13 such actions in 2015.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.